Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma

BACKGROUND: Benralizumab is an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody. Treatment with benralizumab significantly reduces exacerbations and improves lung function after 1 year for patients with severe, uncontrolled eosinophilic asthma. OBJECTIVE: We explored whether benra...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Asthma Allergy
Main Authors: FitzGerald, J Mark, Bleecker, Eugene R, Bourdin, Arnaud, Busse, William W, Ferguson, Gary T, Brooks, Laura, Barker, Peter, Martin, Ubaldo J
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6910092/
https://ncbi.nlm.nih.gov/pubmed/31849500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JAA.S227170
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados